Clinical Pathology, Uppsala University Hospital.
Department of Genetics, Immunology and Pathology.
Ups J Med Sci. 2022 Sep 27;127. doi: 10.48101/ujms.v127.8913. eCollection 2022.
Diagnosis of systemic amyloidosis is a clinical challenge and usually relies on a tissue biopsy. We have developed diagnostic methods based on the presence of amyloid deposits in abdominal subcutaneous fat tissue. This tissue is also used to determine the biochemical type of amyloidosis, performed by western blot and immunohistochemical analyses with the aid of in-house developed rabbit antisera and mouse monoclonal antibodies. Mass spectrometric methods are under development for selected cases. The diagnostic outcome for 2018-2020 was studied. During this period, we obtained 1,562 biopsies, of which 1,397 were unfixed subcutaneous fat tissue with varying degrees of suspicion of systemic amyloidosis. Of these, 440 contained amyloid deposits. The biochemical nature of the amyloid was determined by western blot analysis in 319 specimens and by immunohistochemistry in further 51 cases.
系统性淀粉样变的诊断具有临床挑战性，通常依赖于组织活检。我们已经开发了基于腹部皮下脂肪组织中淀粉样沉积物存在的诊断方法。该组织还用于确定淀粉样变性的生化类型，通过 Western blot 和免疫组织化学分析来完成，使用内部开发的兔抗血清和小鼠单克隆抗体。质谱方法正在为选定的病例开发中。研究了 2018-2020 年的诊断结果。在此期间，我们获得了 1562 个活检样本，其中 1397 个是未经固定的皮下脂肪组织，不同程度怀疑为系统性淀粉样变性。其中，440 个样本含有淀粉样沉积物。通过 Western blot 分析确定了 319 个标本和进一步 51 个标本的淀粉样物质的生化性质。
